AstraZeneca, Merck Report Positive Long-term Data for Lynparza
AstraZeneca Says 87.5% of Lynparza-treated Patients Alive at Six Years in Trial
Express News | Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer
LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
loading...
守株待鹅 : Goddess, which one are you Bullish on?